↓ Skip to main content

Dove Medical Press

IAP proteins as targets for drug development in oncology

Overview of attention for article published in OncoTargets and therapy, September 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
1 X user
patent
1 patent

Citations

dimensions_citation
105 Dimensions

Readers on

mendeley
101 Mendeley
Title
IAP proteins as targets for drug development in oncology
Published in
OncoTargets and therapy, September 2013
DOI 10.2147/ott.s33375
Pubmed ID
Authors

Laurence Dubrez, Jean Berthelet, Valérie Glorian

Abstract

The inhibitors of apoptosis (IAPs) constitute a family of proteins involved in the regulation of various cellular processes, including cell death, immune and inflammatory responses, cell proliferation, cell differentiation, and cell motility. There is accumulating evidence supporting IAP-targeting in tumors: IAPs regulate various cellular processes that contribute to tumor development, such as cell death, cell proliferation, and cell migration; their expression is increased in a number of human tumor samples, and IAP overexpression has been correlated with tumor growth, and poor prognosis or low response to treatment; and IAP expression can be rapidly induced in response to chemotherapy or radiotherapy because of the presence of an internal ribosome entry site (IRES)-dependent mechanism of translation initiation, which could contribute to resistance to antitumor therapy. The development of IAP antagonists is an important challenge and was subject to intense research over the past decade. Six molecules are currently in clinical trials. This review focuses on the role of IAPs in tumors and the development of IAP-targeting molecules for anticancer therapy.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
Mexico 1 <1%
Netherlands 1 <1%
Unknown 97 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 20%
Student > Master 19 19%
Student > Bachelor 14 14%
Researcher 10 10%
Student > Doctoral Student 5 5%
Other 12 12%
Unknown 21 21%
Readers by discipline Count As %
Agricultural and Biological Sciences 26 26%
Biochemistry, Genetics and Molecular Biology 15 15%
Pharmacology, Toxicology and Pharmaceutical Science 10 10%
Medicine and Dentistry 10 10%
Chemistry 8 8%
Other 7 7%
Unknown 25 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2023.
All research outputs
#7,959,162
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#431
of 3,016 outputs
Outputs of similar age
#65,334
of 212,459 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 35 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,459 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.